Entering text into the input field will update the search result below

Cellectis S.A. (CLLS) CEO André Choulika on Q4 2020 Results - Earnings Call Transcript

Mar. 05, 2021 3:15 PM ETCellectis S.A. (CLLS), CMVLF
SA Transcripts profile picture
SA Transcripts

Cellectis S.A. (NASDAQ:CLLS) Q4 2020 Earnings Conference Call March 5, 2021 8:00 AM ET

Company Participants

Simon Harnest - Senior Vice President, Corporate Strategy and Finance

André Choulika - Chief Executive Officer

Carrie Brownstein - Chief Medical Officer

Eric Dutang - Chief Financial Officer

Conference Call Participants

Michael Schmidt - Guggenheim Securities, LLC

Gena Wang - Barclays

Salveen Richter - Goldman Sachs

Hartaj Singh - Oppenheimer & Company

Yigal Nochomovitz - Citigroup

Wangzhi Li - Ladenburg Thalmann

Biren Amin - Jefferies LLC

Nick Abbott - Wells Fargo Securities LLC

Samantha Corwin - William Blair & Company

Jack Allen - Baird

Soumit Roy - JonesTrading


Greetings. Welcome to the Cellectis Fourth Quarter and Full Year 2020 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.

At this time, I will turn the conference over to Simon Harnest, Chief Investment Officer. Simon, you may begin.

Simon Harnest

Thank you, and welcome, everyone to Cellectis fourth quarter and full year corporate update and financial results conference call for the 2020 fiscal year. Joining me on the call today with prepared remarks are Dr. André Choulika, our Chief Executive Officer; Dr. Carrie Brownstein, our Chief Medical Officer; and Eric Dutang, our Chief Financial Officer.

Yesterday evening, Cellectis filed its annual report and issued a press release reporting our financial results for the fourth quarter and year ending December 31, 2020. These reports and press releases are available on our website at cellectis.com.

As a reminder, we will make forward-looking statements regarding Cellectis financial outlook in addition to its regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About CLLS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CLLS

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.